H.R. 2707 · 118th Congress (2023–2025)
MADE in America Act
This bill establishes a tax credit for certain manufacturers of pharmaceuticals or medical products.
Specifically, the bill establishes a tax credit for manufacturers of pharmaceuticals, active pharmaceutical ingredients, excipients (i.e., inactive ingredients), medical diagnostic devices, or personal protective equipment, if they are located in a designated distressed zone. The tax credit is equal to 25% of the manufacturer's production expenditures; the credit increases to 30% of expenditures if a substantial portion of the manufacturer's employees reside in a distressed zone.
The bill defines distressed zone as an area that has been designated as a qualified opportunity zone by the Internal Revenue Service (i.e., an economically distressed community in which certain new investments may be eligible for preferential tax treatment) and that has a poverty rate of over 30%.
Show official title
To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 2707’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Earl L. "Buddy" Carter (R-GA-1)
- Cosponsors
13 cosponsors
11 original · 2 later
11 R · 2 D
- Rep. Gus M. Bilirakis (R-FL-12)· Original · Apr 19, 2023
- Rep. Troy Balderson (R-OH-12)· Original · Apr 19, 2023
- Rep. Eric A. "Rick" Crawford (R-AR-1)· Original · Apr 19, 2023
- Rep. Matt Cartwright (D-PA-8)· Original · Apr 19, 2023
- Rep. H. Morgan Griffith (R-VA-9)· Original · Apr 19, 2023
- Rep. Richard Hudson (R-NC-9)· Original · Apr 19, 2023
- Rep. Diana Harshbarger (R-TN-1)· Original · Apr 19, 2023
- Rep. Nicholas A. Langworthy (R-NY-23)· Original · Apr 19, 2023
- Rep. Carol D. Miller (R-WV-1)· Original · Apr 19, 2023
- Rep. Darren Soto (D-FL-9)· Original · Apr 19, 2023
- Rep. Jefferson Van Drew (R-NJ-2)· Original · Apr 19, 2023
- Rep. Ronny Jackson (R-TX-13)· Later · May 23, 2023
- Rep. John H. Rutherford (R-FL-5)· Later · Jan 17, 2024
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Apr 19, 2023 – Dec 17, 2024
Referred to committee
Referred to the House Committee on Ways and Means.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (3)
MADE in America Act
Display title, Short title · Introduced in House
Manufacturing API, Drugs, and Excipients in America Act
Short title · Introduced in House
To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.
Official title · Introduced in House